{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:55:14Z","timestamp":1793141714415,"version":"4.5.0"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.coi.2026.102759","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T15:45:27Z","timestamp":1774885527000},"page":"102759","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["From disease to syndrome: the evolution of Parkinson\u2019s as a heterogeneous entity"],"prefix":"10.1016","volume":"100","author":[{"given":"Kishore Raj","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zg\u00fcr \u00d6ztop","family":"\u00c7akmak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1339-243X","authenticated-orcid":false,"given":"Sibel","family":"Ertan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2026.102759_bib1","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/mds.25844","article-title":"Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease","volume":"29","author":"Berg","year":"2014","journal-title":"Mov Disord"},{"key":"10.1016\/j.coi.2026.102759_sbref2","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/mds.29419","article-title":"Defining the riddle in order to solve it: there is more than one \u201cParkinson\u2019s disease\u201d","volume":"38","author":"Outeiro","year":"2023","journal-title":"Mov Disord"},{"key":"10.1016\/j.coi.2026.102759_bib3","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","article-title":"A biological definition of neuronal alpha-synuclein disease: towards an integrated staging system for research","volume":"23","author":"Simuni","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.coi.2026.102759_sbref4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","article-title":"A biological classification of Parkinson\u2019s disease: the SynNeurGe research diagnostic criteria","volume":"23","author":"Hoglinger","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.coi.2026.102759_bib5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1176\/jnp.14.2.223","article-title":"An essay on the shaking palsy. 1817","volume":"14","author":"Parkinson","year":"2002","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.coi.2026.102759_bib6","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/mds.27115","article-title":"Past, present, and future of Parkinson's disease: a special essay on the 200th Anniversary of the Shaking Palsy","volume":"32","author":"Obeso","year":"2017","journal-title":"Mov Disord"},{"key":"10.1016\/j.coi.2026.102759_bib7","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov Disord"},{"key":"10.1016\/j.coi.2026.102759_bib8","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/mds.26431","article-title":"MDS research criteria for prodromal Parkinson's disease","volume":"30","author":"Berg","year":"2015","journal-title":"Mov Disord"},{"key":"10.1016\/j.coi.2026.102759_bib9","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/mds.26510","article-title":"Nonmotor features of Parkinson's disease subtypes","volume":"31","author":"Marras","year":"2016","journal-title":"Mov Disord"},{"key":"10.1016\/j.coi.2026.102759_bib10","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/bs.irn.2017.05.011","article-title":"Nonmotor subtyping in Parkinson's disease","volume":"133","author":"Sauerbier","year":"2017","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.coi.2026.102759_sbref11","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(23)01419-8","article-title":"The epidemiology of Parkinson\u2019s disease","volume":"403","author":"Ben-Shlomo","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2026.102759_bib12","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1017\/S0317167100010209","article-title":"Substantia nigra and Parkinson's disease: a brief history of their long and intimate relationship","volume":"37","author":"Parent","year":"2010","journal-title":"Can J Neurol Sci"},{"issue":"Pt 8","key":"10.1016\/j.coi.2026.102759_bib13","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1093\/brain\/awt192","article-title":"Disease duration and the integrity of the nigrostriatal system in Parkinson's disease","volume":"136","author":"Kordower","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.coi.2026.102759_bib14","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3390\/jpm15050172","article-title":"Redefining non-motor symptoms in Parkinson\u2019s disease","volume":"15","author":"Pena-Zelayeta","year":"2025","journal-title":"J Pers Med"},{"key":"10.1016\/j.coi.2026.102759_bib15","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2174\/011570159X336597241217062042","article-title":"Synaptic interactions between serotonergic and dopaminergic systems in Parkinson's disease","volume":"23","author":"Marino","year":"2025","journal-title":"Curr Neuropharmacol"},{"issue":"Pt 9","key":"10.1016\/j.coi.2026.102759_bib16","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/brain\/awu193","article-title":"Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease","volume":"137","author":"Hall","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.coi.2026.102759_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/jnr.25322","article-title":"The role of orexin in Parkinson's disease","volume":"102","author":"Braun","year":"2024","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.coi.2026.102759_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2024.105760","article-title":"The misfolding mystery: alpha-synuclein and the pathogenesis of Parkinson's disease","volume":"177","author":"Negi","year":"2024","journal-title":"Neurochem Int"},{"key":"10.1016\/j.coi.2026.102759_bib19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1146\/annurev-pathmechdis-031521-034145","article-title":"Genetics and pathogenesis of Parkinson's syndrome","volume":"18","author":"Ye","year":"2023","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.coi.2026.102759_bib20","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/acn3.51776","article-title":"LRRK2 and Parkinson's disease: from genetics to targeted therapy","volume":"10","author":"Sosero","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.coi.2026.102759_sbref21","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.3390\/ijms26072942","article-title":"Concomitant pathologies and their impact on Parkinson disease: a narrative overview of current evidence","volume":"26","author":"Jellinger","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coi.2026.102759_bib22","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1093\/brain\/awy146","article-title":"Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated","volume":"141","author":"Robinson","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.coi.2026.102759_bib23","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00401-007-0261-2","article-title":"Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases","volume":"114","author":"Nakashima-Yasuda","year":"2007","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.coi.2026.102759_bib24","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3389\/fneur.2018.00809","article-title":"Tau pathology in Parkinson's disease","volume":"9","author":"Zhang","year":"2018","journal-title":"Front Neurol"},{"key":"10.1016\/j.coi.2026.102759_sbref25","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/brain\/awad388","article-title":"Nigrostriatal tau pathology in parkinsonism and Parkinson\u2019s disease","volume":"147","author":"Chu","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.coi.2026.102759_bib26","doi-asserted-by":"crossref","first-page":"6517","DOI":"10.3390\/ijms22126517","article-title":"Alpha-synuclein as a prominent actor in the inflammatory synaptopathy of Parkinson\u2019s disease","volume":"22","author":"Cardinale","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coi.2026.102759_sbref27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2025.578716","article-title":"Immunity in Parkinson\u2019s disease \u2014 the role of innate responses","volume":"408","author":"Iyengar","year":"2025","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.coi.2026.102759_bib28","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1515\/nipt-2025-0008","article-title":"Adaptive immunity in the pathogenesis and treatments of Parkinson's disease","volume":"4","author":"Du","year":"2025","journal-title":"NeuroImmune Pharm Ther"},{"key":"10.1016\/j.coi.2026.102759_sbref29","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1093\/brain\/awae177","article-title":"The immune system in Parkinson\u2019s disease: what we know so far","volume":"147","author":"Roodveldt","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.coi.2026.102759_bib30","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/acn3.580","article-title":"Immunosuppressants and risk of Parkinson disease","volume":"5","author":"Racette","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.coi.2026.102759_bib31","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1212\/WNL.38.8.1285","article-title":"Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains","volume":"38","author":"McGeer","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/j.coi.2026.102759_bib32","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1001\/jamaneurol.2016.2742","article-title":"Aberrations in peripheral inflammatory cytokine levels in Parkinson disease: a systematic review and meta-analysis","volume":"73","author":"Qin","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.coi.2026.102759_bib33","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/mds.26563","article-title":"Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD)","volume":"31","author":"Williams-Gray","year":"2016","journal-title":"Mov Disord"},{"key":"10.1016\/j.coi.2026.102759_bib34","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.3389\/fimmu.2018.02122","article-title":"Cerebrospinal fluid inflammatory cytokine aberrations in Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis: a systematic review and meta-analysis","volume":"9","author":"Chen","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2026.102759_bib35","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1474-4422(19)30320-5","article-title":"Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies","volume":"18","author":"Nalls","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.coi.2026.102759_bib36","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1042\/BST20180462","article-title":"LRRK2 links genetic and sporadic Parkinson's disease","volume":"47","author":"Kluss","year":"2019","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.coi.2026.102759_bib37","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41582-020-0344-4","article-title":"Parkinson disease and the immune system \u2014 associations, mechanisms and therapeutics","volume":"16","author":"Tan","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.coi.2026.102759_bib38","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/s41467-020-15626-w","article-title":"\u03b1-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson's disease","volume":"11","author":"Lindestam Arlehamn","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2026.102759_bib39","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2020858118","article-title":"Monocyte markers correlate with immune and neuronal brain changes in REM sleep behavior disorder","volume":"118","author":"Farmen","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coi.2026.102759_bib40","doi-asserted-by":"crossref","first-page":"9302","DOI":"10.3390\/ijms21239302","article-title":"New insights into immune-mediated mechanisms in Parkinson\u2019s disease","volume":"21","author":"Tan","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coi.2026.102759_bib41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bbi.2019.06.042","article-title":"Toll-like receptors and their therapeutic potential in Parkinson's disease and \u03b1-synucleinopathies","volume":"81","author":"Kouli","year":"2019","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.coi.2026.102759_bib42","doi-asserted-by":"crossref","first-page":"7243","DOI":"10.3390\/jcm13237243","article-title":"Alpha-synuclein and microglia in Parkinson\u2019s disease: from pathogenesis to therapeutic prospects","volume":"13","author":"Eo","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.coi.2026.102759_bib43","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nature22815","article-title":"T cells from patients with Parkinson's disease recognize \u03b1-synuclein peptides","volume":"546","author":"Sulzer","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.coi.2026.102759_bib44","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/nature23896","article-title":"Erratum: T cells from patients with Parkinson's disease recognize \u03b1-synuclein peptides","volume":"549","author":"Sulzer","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.coi.2026.102759_bib45","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12974-022-02496-w","article-title":"The role of Toll-like receptors and neuroinflammation in Parkinson's disease","volume":"19","author":"Heidari","year":"2022","journal-title":"J Neuroinflamm"},{"key":"10.1016\/j.coi.2026.102759_bib46","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coi.2026.102759_bib47","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41531-018-0061-5","article-title":"expression in mesencephalic neurons and characterization of a rare","volume":"4","author":"von Herrmann","year":"2018","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1016\/j.coi.2026.102759_bib48","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40035-020-00221-2","article-title":"Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes","volume":"9","author":"Kwon","year":"2020","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.coi.2026.102759_sbref49","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.bbi.2024.10.007","article-title":"Frontiers of neurodegenerative disease treatment: targeting immune cells in brain border regions","volume":"123","author":"Satyanarayanan","year":"2025","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.coi.2026.102759_bib50","doi-asserted-by":"crossref","first-page":"fcad060","DOI":"10.1093\/braincomms\/fcad060","article-title":"B lymphocyte responses in Parkinson's disease and their possible significance in disease progression","volume":"5","author":"Scott","year":"2023","journal-title":"Brain Commun"},{"key":"10.1016\/j.coi.2026.102759_bib51","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3233\/JPD-240272","article-title":"Parkinson's disease drug therapies in the clinical trial pipeline: 2024 update","volume":"14","author":"McFarthing","year":"2024","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.coi.2026.102759_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.879021","article-title":"The NLRP3 inflammasome pathway: a review of mechanisms and inhibitors for the treatment of inflammatory diseases","volume":"14","author":"Blevins","year":"2022","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.coi.2026.102759_bib53","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.3390\/ijms25084330","article-title":"Experimental models to study immune dysfunction in the pathogenesis of Parkinson\u2019s disease","volume":"25","author":"Saponjic","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coi.2026.102759_bib54","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/brain\/awaf419","article-title":"Faecal microbiota transplant for Parkinson\u2019s disease: promises and future directions","volume":"149","author":"Tan","year":"2025","journal-title":"Brain"},{"key":"10.1016\/j.coi.2026.102759_bib55","article-title":"Uses of fecal microbiota transplantation in neurodegenerative disease: a scoping review","volume":"16","author":"Sanzone","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.coi.2026.102759_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1104759","article-title":"Fecal microbiota transplantation in Parkinson's disease \u2014 a randomized repeat-dose, placebo-controlled clinical pilot study","volume":"14","author":"DuPont","year":"2023","journal-title":"Front Neurol"},{"key":"10.1016\/j.coi.2026.102759_bib57","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bbi.2018.02.005","article-title":"Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson's disease mice: gut microbiota, glial reaction and TLR4\/TNF-\u03b1 signaling pathway","volume":"70","author":"Sun","year":"2018","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.coi.2026.102759_bib58","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41582-022-00681-2","article-title":"The microbiome-gut-brain axis in Parkinson disease \u2014 from basic research to the clinic","volume":"18","author":"Tan","year":"2022","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.coi.2026.102759_bib59","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S1474-4422(19)30287-X","article-title":"The genetic architecture of Parkinson's disease","volume":"19","author":"Blauwendraat","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.coi.2026.102759_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.1023574","article-title":"Genetic architecture of Parkinson's disease subtypes \u2014 review of the literature","volume":"14","author":"Dulski","year":"2022","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.coi.2026.102759_bib61","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41531-025-01150-5","article-title":"A multi-dimensional view on the etiology of Parkinson's disease","volume":"11","author":"Bernhardt","year":"2025","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1016\/j.coi.2026.102759_bib62","first-page":"67","article-title":"Genetic basis of Parkinson's disease: inheritance, penetrance, and expression","volume":"4","author":"Schulte","year":"2011","journal-title":"Appl Clin Genet"},{"key":"10.1016\/j.coi.2026.102759_bib63","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41531-020-0110-8","article-title":"Genetic predispositions of Parkinson's disease revealed in patient-derived brain cells","volume":"6","author":"Tran","year":"2020","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1016\/j.coi.2026.102759_bib64","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1002\/mds.70037","article-title":"RAB32-linked Parkinson\u2019s disease: deep phenotyping, MDSGene literature review, and application of SynNeurGe criteria","volume":"40","author":"Kleinz","year":"2025","journal-title":"Mov Disord"},{"key":"10.1016\/j.coi.2026.102759_sbref65","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41588-023-01584-8","article-title":"Multi-ancestry genome-wide association meta-analysis of Parkinson\u2019s disease","volume":"56","author":"Kim","year":"2024","journal-title":"Nat Genet"},{"key":"10.1016\/j.coi.2026.102759_bib66","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00702-023-02635-4","article-title":"The heterogeneity of Parkinson's disease","volume":"130","author":"W\u00fcllner","year":"2023","journal-title":"J Neural Transm"},{"key":"10.1016\/j.coi.2026.102759_bib67","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3390\/genes13030471","article-title":"Monogenic Parkinson\u2019s disease: genotype, phenotype, pathophysiology, and genetic testing","volume":"13","author":"Jia","year":"2022","journal-title":"Genes"},{"key":"10.1016\/j.coi.2026.102759_bib68","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1212\/WNL.0000000000001315","article-title":"Differential effects of severe vs mild GBA mutations on Parkinson disease","volume":"84","author":"Gan-Or","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.coi.2026.102759_bib69","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/mds.29288","article-title":"Embracing monogenic Parkinson's disease: the MJFF Global Genetic PD Cohort","volume":"38","author":"Vollstedt","year":"2023","journal-title":"Mov Disord"},{"key":"10.1016\/j.coi.2026.102759_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.648588","article-title":"Genotype-phenotype correlations in monogenic Parkinson disease: a review on clinical and molecular findings","volume":"12","author":"Guadagnolo","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.coi.2026.102759_bib71","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1055\/s-0037-1601567","article-title":"Genetic forms of Parkinson's disease","volume":"37","author":"Kim","year":"2017","journal-title":"Semin Neurol"},{"key":"10.1016\/j.coi.2026.102759_bib72","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1136\/jnnp-2011-301205","article-title":"Molecular pathogenesis of Parkinson's disease: update","volume":"83","author":"Saiki","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.coi.2026.102759_bib73","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s13760-025-02897-7","article-title":"Elucidate biomarkers and the molecular pathways associated with genetic variants that contribute to the etiology of Parkinson's disease","volume":"125","author":"Nguyen","year":"2025","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.coi.2026.102759_bib74","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/mds.27895","article-title":"The vicious cycle between \u03b1-synuclein aggregation and autophagic-lysosomal dysfunction","volume":"35","author":"Bellomo","year":"2020","journal-title":"Mov Disord"},{"key":"10.1016\/j.coi.2026.102759_bib75","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1016\/j.jmb.2020.01.037","article-title":"Autophagy in Parkinson's disease","volume":"432","author":"Hou","year":"2020","journal-title":"J Mol Biol"},{"key":"10.1016\/j.coi.2026.102759_bib76","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/mds.27193","article-title":"Neuropathology of genetic synucleinopathies with parkinsonism: review of the literature","volume":"32","author":"Schneider","year":"2017","journal-title":"Mov Disord"},{"key":"10.1016\/j.coi.2026.102759_bib77","article-title":"Neuropathology in genetic Parkinson\u2019s disease: a focused review of pathological and clinical findings","volume":"22","author":"Barbosa","year":"2025","journal-title":"J Neural Transm"},{"key":"10.1016\/j.coi.2026.102759_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2024.107146","article-title":"Genetic heterogeneity of early onset Parkinson disease: the dilemma of clinico-genetic correlation","volume":"129","author":"Rajan","year":"2024","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.coi.2026.102759_bib79","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/978-3-319-49969-7_2","article-title":"Clinical features of LRRK2 carriers with Parkinson's disease","volume":"14","author":"Kestenbaum","year":"2017","journal-title":"Adv Neurobiol"},{"key":"10.1016\/j.coi.2026.102759_bib80","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.tins.2021.12.002","article-title":"LRRK2 and idiopathic Parkinson's disease","volume":"45","author":"Rocha","year":"2022","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.coi.2026.102759_bib81","doi-asserted-by":"crossref","first-page":"eadv1434","DOI":"10.1126\/sciadv.adv1434","article-title":"GPNMB is a biomarker for lysosomal dysfunction and is secreted via LRRK2-modulated lysosomal exocytosis","volume":"11","author":"Bogacki","year":"2025","journal-title":"Sci Adv"},{"key":"10.1016\/j.coi.2026.102759_bib82","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ceb.2019.05.003","article-title":"Lysosome-related organelles as functional adaptations of the endolysosomal system","volume":"59","author":"Delevoye","year":"2019","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.coi.2026.102759_bib83","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s00415-025-13148-3","article-title":"Neuropathological examination of 12 cases of familial Parkinson's disease with LRRK2 I2020T mutation including tau and TDP-43 pathology","volume":"272","author":"Uchino","year":"2025","journal-title":"J Neurol"},{"key":"10.1016\/j.coi.2026.102759_bib84","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1002\/mds.27527","article-title":"Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35: MDSGene systematic review","volume":"33","author":"Trinh","year":"2018","journal-title":"Mov Disord"},{"key":"10.1016\/j.coi.2026.102759_bib85","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/archneurol.2011.3367","article-title":"Frequency of the D620N mutation in VPS35 in Parkinson disease","volume":"69","author":"Kumar","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.coi.2026.102759_bib86","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.parkreldis.2021.02.014","article-title":"Clinical manifestations of Parkinson's disease harboring VPS35 retromer complex component p.D620N with long-term follow-up","volume":"84","author":"Ishiguro","year":"2021","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.coi.2026.102759_bib87","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1093\/hmg\/ddac142","article-title":"Mutant VPS35-D620N induces motor dysfunction and impairs DAT-mediated dopamine recycling pathway","volume":"31","author":"Huang","year":"2022","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.coi.2026.102759_bib88","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.parkreldis.2016.12.001","article-title":"Role of the VPS35 D620N mutation in Parkinson's disease","volume":"36","author":"Mohan","year":"2017","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.coi.2026.102759_bib89","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2025.1692687","article-title":"VPS35 D620N mutation impairs neurogenesis and promotes ferroptosis in Parkinson's disease by using molecular docking, molecular dynamic simulation, and cellular model","volume":"17","author":"Jiang","year":"2025","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.coi.2026.102759_bib90","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awaf414","article-title":"VPS35 mutation inhibits PINK1\/parkin-mediated mitophagy via increased LRRK2 kinase activity","author":"Manders","year":"2025","journal-title":"Brain"},{"key":"10.1016\/j.coi.2026.102759_bib91","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1038\/ncomms4828","article-title":"Mutation in VPS35 associated with Parkinson's disease impairs WASH complex association and inhibits autophagy","volume":"5","author":"Zavodszky","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.coi.2026.102759_bib92","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.celrep.2015.08.001","article-title":"VPS35 deficiency or mutation causes dopaminergic neuronal loss by impairing mitochondrial fusion and function","volume":"12","author":"Tang","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.coi.2026.102759_bib93","doi-asserted-by":"crossref","first-page":"5765","DOI":"10.1073\/pnas.1814909116","article-title":"Parkinson's disease-linked","volume":"116","author":"Chen","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coi.2026.102759_bib94","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10571-020-00849-8","article-title":"The role of VPS35 in the pathobiology of Parkinson's disease","volume":"41","author":"Sassone","year":"2021","journal-title":"Cell Mol Neurobiol"},{"key":"10.1016\/j.coi.2026.102759_bib95","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1474-4422(24)00121-2","article-title":"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","volume":"23","author":"Gustavsson","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.coi.2026.102759_bib96","doi-asserted-by":"crossref","first-page":"38","DOI":"10.5603\/pjnns.97806","article-title":"Genetics of Parkinson's disease: state-of-the-art and role in clinical settings","volume":"58","author":"Dulski","year":"2024","journal-title":"Neurol Neurochir Pol"},{"key":"10.1016\/j.coi.2026.102759_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105433","article-title":"Role of mitophagy in mitochondrial quality control: mechanisms and potential implications for neurodegenerative diseases","volume":"165","author":"Wang","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.coi.2026.102759_bib98","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41531-024-00677-3","article-title":"Genotype-phenotype correlation in PRKN-associated Parkinson's disease","volume":"10","author":"Menon","year":"2024","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1016\/j.coi.2026.102759_bib99","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.pneurobio.2018.09.003","article-title":"New insights into the complex role of mitochondria in Parkinson's disease","volume":"177","author":"Gr\u00fcnewald","year":"2019","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.coi.2026.102759_bib100","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41419-022-05339-x","article-title":"Novel protein complexes containing autophagy and UPS components regulate proteasome-dependent PARK2 recruitment onto mitochondria and PARK2-PARK6 activity during mitophagy","volume":"13","author":"Kocaturk","year":"2022","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.coi.2026.102759_bib101","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1073\/pnas.0501282102","article-title":"Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress","volume":"102","author":"Kim","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coi.2026.102759_bib102","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/jcm8091377","article-title":"DJ-1 in Parkinson\u2019s disease: clinical insights and therapeutic perspectives","volume":"8","author":"Repici","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.coi.2026.102759_bib103","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12964-025-02136-9","article-title":"Neuroprotective role and mechanistic insights of DJ-1 dimerization in Parkinson's disease","volume":"23","author":"Lv","year":"2025","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.coi.2026.102759_bib104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuroscience.2025.09.025","article-title":"DJ-1\/PARK7 in Parkinson's disease: mechanisms of pathogenesis and therapeutic potential","volume":"587","author":"Bao","year":"2025","journal-title":"Neuroscience"},{"issue":"Pt 6","key":"10.1016\/j.coi.2026.102759_bib105","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1093\/brain\/aww080","article-title":"DJ-1 linked parkinsonism (PARK7) is associated with Lewy body pathology","volume":"139","author":"Taipa","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.coi.2026.102759_bib106","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/mds.29126","article-title":"Underrepresented populations in Parkinson's genetics research: current landscape and future directions","volume":"37","author":"Schumacher-Schuh","year":"2022","journal-title":"Mov Disord"},{"key":"10.1016\/j.coi.2026.102759_bib107","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/mds.29342","article-title":"Polygenic Parkinson's disease genetic risk score as risk modifier of parkinsonism in Gaucher disease","volume":"38","author":"Blauwendraat","year":"2023","journal-title":"Mov Disord"},{"key":"10.1016\/j.coi.2026.102759_bib108","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00415-025-13472-8","article-title":"The development and emerging trends in Parkinson's disease from the perspective of mitochondrial dysfunction: a bibliometric analysis using CiteSpace","volume":"272","author":"Lu","year":"2025","journal-title":"J Neurol"},{"key":"10.1016\/j.coi.2026.102759_bib109","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.tins.2018.09.007","article-title":"Triggers, facilitators, and aggravators: redefining Parkinson's disease pathogenesis","volume":"42","author":"Johnson","year":"2019","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.coi.2026.102759_sbref110","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2024.106101","article-title":"Brain-first vs. body-first Parkinson\u2019s disease: an update on recent evidence","volume":"122","author":"Horsager","year":"2024","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.coi.2026.102759_bib111","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00702-016-1667-6","article-title":"Parkinson's: a syndrome rather than a disease?","volume":"124","author":"Titova","year":"2017","journal-title":"J Neural Transm"},{"key":"10.1016\/j.coi.2026.102759_fur1","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/mds.29297","article-title":"LRRK2 inhibition by BIIB122 in healthy participants and patients with Parkinson\u2019s disease","volume":"38","author":"Jennings","year":"2023","journal-title":"Mov Disord"},{"key":"10.1016\/j.coi.2026.102759_fur2","doi-asserted-by":"crossref","first-page":"6094","DOI":"10.3390\/ijms26136094","article-title":"LC-MS\/MS-based determination of ambroxol in human plasma and cerebrospinal fluid: validation and applicability in a phase II study on GBA-associated Parkinson\u2019s disease patients","volume":"26","author":"Franco","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coi.2026.102759_fur3","article-title":"Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in","volume":"5","author":"Colucci","year":"2023","journal-title":"BMJ Neurol Open"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791526000361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791526000361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T04:21:58Z","timestamp":1779510118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791526000361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":114,"alternative-id":["S0952791526000361"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2026.102759","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From disease to syndrome: the evolution of Parkinson\u2019s as a heterogeneous entity","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2026.102759","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102759"}}